Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.38 |
| ▸ | YAP1 | P46937 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 2/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5170881 | 0.90 | GPR119 (0.48) | GPR119ESR2NR1H2NPC1RAB9A | |
| SCHEMBL5663494 | 0.89 | GPR119 (0.47) | GPR119ESR2NR1H2NPC1RAB9A | |
| SCHEMBL5172059 | 0.86 | ESR2 (0.47) | GPR119ESR2NR1H2NPC1RAB9A | |
| SCHEMBL5169420 | 0.84 | GPR119 (0.50) | GPR119ESR2NR1H2NPC1RAB9A | |
| SCHEMBL5171654 | 0.81 | ESR2 (0.47) | GPR119ESR2NR1H2NPC1RAB9A | |
| SCHEMBL5662249 | 0.79 | ESR2 (0.46) | GPR119ESR2NR1H2NPC1RAB9A | |
| SCHEMBL5664186 | 0.79 | GPR119 (0.49) | GPR119ESR2NR1H2NPC1RAB9A | |
| SCHEMBL5662459 | 0.78 | GPR119 (0.48) | GPR119ESR2NR1H2NPC1RAB9A | |
| SCHEMBL5663564 | 0.78 | HRH3 (0.48) | GPR119ESR2NR1H2NPC1RAB9A | |
| SCHEMBL5170986 | 0.77 | ESR2 (0.46) | GPR119ESR2NR1H2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-09-06 | — | — | US | disclosed |
| EP-1778643-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006018260-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H 3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | GPR119 130/4885ESR2 938/4885NR1H2 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.